Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- New Study Links Skeleton with Obesity and Diabetes
A study in the journal Cell, “Endocrine Regulation of Energy Metabolism by the Skeleton”, links the vitamin K-dependent protein Osteocalcin to insulin activity and the reduction of obesity and diabetes in mice.
- New Study Links Skeleton with Obesity and Diabetes
A study in the journal Cell, “Endocrine Regulation of Energy Metabolism by the Skeleton”, links the vitamin K-dependent protein Osteocalcin to insulin activity and the reduction of obesity and diabetes in mice.
- Scientific Research Indicates That TOYO-FVG(TM) and Astaxanthin Combination Effective for Diabetes Complications
According to Toyo Shinyaku Co., Ltd., parent company of Toyo Bio-Pharma(TM), joint research presented as a white paper at the 61st Annual Meeting of the Japanese Society of Nutrition and Food Science indicates that TOYO-FVG and Astaxanthin, used in combination, demonstrated an inhibitory effect on oxidative stress.
- Scientific Research Indicates That TOYO-FVG(TM) and Astaxanthin Combination Effective for Diabetes Complications
According to Toyo Shinyaku Co., Ltd., parent company of Toyo Bio-Pharma(TM), joint research presented as a white paper at the 61st Annual Meeting of the Japanese Society of Nutrition and Food Science indicates that TOYO-FVG and Astaxanthin, used in combination, demonstrated an inhibitory effect on oxidative stress.
- Scientific Research Indicates That TOYO-FVG(TM) and Astaxanthin Combination Effective for Diabetes Complications
According to Toyo Shinyaku Co., Ltd., parent company of Toyo Bio-Pharma(TM), joint research presented as a white paper at the 61st Annual Meeting of the Japanese Society of Nutrition and Food Science indicates that TOYO-FVG and Astaxanthin, used in combination, demonstrated an inhibitory effect on oxidative stress.
- Beneficial Effects of Salba (A Novel Whole-Grain) Intake on Cardiovascular Risk Factors in Diabetes
Researchers from Toronto's St. Michael's Hospital observed that long term supplementation with Salba - a novel whole-grain (Salvia hispanica L.), rich in fiber, alpha-linolenic acid and minerals, "attenuated a major cardiovascular risk factor ... safely beyond conventional therapy, while maintaining good glycemic and lipid control in people with well-controlled type 2 diabetes."
- Beneficial Effects of Salba (A Novel Whole-Grain) Intake on Cardiovascular Risk Factors in Diabetes
Researchers from Toronto's St. Michael's Hospital observed that long term supplementation with Salba - a novel whole-grain (Salvia hispanica L.), rich in fiber, alpha-linolenic acid and minerals, "attenuated a major cardiovascular risk factor ... safely beyond conventional therapy, while maintaining good glycemic and lipid control in people with well-controlled type 2 diabetes."
- Beneficial Effects of Salba (A Novel Whole-Grain) Intake on Cardiovascular Risk Factors in Diabetes
Researchers from Toronto's St. Michael's Hospital observed that long term supplementation with Salba - a novel whole-grain (Salvia hispanica L.), rich in fiber, alpha-linolenic acid and minerals, "attenuated a major cardiovascular risk factor ... safely beyond conventional therapy, while maintaining good glycemic and lipid control in people with well-controlled type 2 diabetes."
- Study Validates the Benefits of SDG Flax Lignans in Patients With Impaired Glycemic Control
The results of randomized, controlled crossover study, published in onlne peer-reviewed journal PLoS (PloS.org) the effects of 360 mg per day SDG flax lignans were investigated in 68 Type 2 diabetic patients. The study utilized Jarrow Formulas Flax Essence(TM) as the source material.
- Study Validates the Benefits of SDG Flax Lignans in Patients With Impaired Glycemic Control
The results of randomized, controlled crossover study, published in onlne peer-reviewed journal PLoS (PloS.org) the effects of 360 mg per day SDG flax lignans were investigated in 68 Type 2 diabetic patients. The study utilized Jarrow Formulas Flax Essence(TM) as the source material.
- Study Validates the Benefits of SDG Flax Lignans in Patients With Impaired Glycemic Control
The results of randomized, controlled crossover study, published in onlne peer-reviewed journal PLoS (PloS.org) the effects of 360 mg per day SDG flax lignans were investigated in 68 Type 2 diabetic patients. The study utilized Jarrow Formulas Flax Essence(TM) as the source material.
- Study Validates the Benefits of SDG Flax Lignans in Patients With Impaired Glycemic Control
The results of randomized, controlled crossover study, published in onlne peer-reviewed journal PLoS (PloS.org) the effects of 360 mg per day SDG flax lignans were investigated in 68 Type 2 diabetic patients. The study utilized Jarrow Formulas Flax Essence(TM) as the source material.
- Study Validates the Benefits of SDG Flax Lignans in Patients With Impaired Glycemic Control
The results of randomized, controlled crossover study, published in onlne peer-reviewed journal PLoS (PloS.org) the effects of 360 mg per day SDG flax lignans were investigated in 68 Type 2 diabetic patients. The study utilized Jarrow Formulas Flax Essence(TM) as the source material.
- Study Validates the Benefits of SDG Flax Lignans in Patients With Impaired Glycemic Control
The results of randomized, controlled crossover study, published in onlne peer-reviewed journal PLoS (PloS.org) the effects of 360 mg per day SDG flax lignans were investigated in 68 Type 2 diabetic patients. The study utilized Jarrow Formulas Flax Essence(TM) as the source material.
- Vitamin E Could Help 40% of Diabetics Ward off Heart Attacks According to the Technion-Israel Institute of Technology
According to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel, citing a study published in the November 21 online edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology, people with the haptoglobin (Hp) 2-2 gene who took 400 International Units (IU) of vitamin E daily had more than 50 percent fewer heart attacks, strokes, and related deaths than Hp 2-2 patients who took a placebo pill. 40% of individuals with diabetes carry the Hp 2-2 gene.
- Vitamin E Could Help 40% of Diabetics Ward off Heart Attacks According to the Technion-Israel Institute of Technology
According to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel, citing a study published in the November 21 online edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology, people with the haptoglobin (Hp) 2-2 gene who took 400 International Units (IU) of vitamin E daily had more than 50 percent fewer heart attacks, strokes, and related deaths than Hp 2-2 patients who took a placebo pill. 40% of individuals with diabetes carry the Hp 2-2 gene.
- Vitamin E Could Help 40% of Diabetics Ward off Heart Attacks According to the Technion-Israel Institute of Technology
According to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel, citing a study published in the November 21 online edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology, people with the haptoglobin (Hp) 2-2 gene who took 400 International Units (IU) of vitamin E daily had more than 50 percent fewer heart attacks, strokes, and related deaths than Hp 2-2 patients who took a placebo pill. 40% of individuals with diabetes carry the Hp 2-2 gene.
- Vitamin E Could Help 40% of Diabetics Ward off Heart Attacks According to the Technion-Israel Institute of Technology
According to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel, citing a study published in the November 21 online edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology, people with the haptoglobin (Hp) 2-2 gene who took 400 International Units (IU) of vitamin E daily had more than 50 percent fewer heart attacks, strokes, and related deaths than Hp 2-2 patients who took a placebo pill. 40% of individuals with diabetes carry the Hp 2-2 gene.
- Vitamin E Could Help 40% of Diabetics Ward off Heart Attacks According to the Technion-Israel Institute of Technology
According to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel, citing a study published in the November 21 online edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology, people with the haptoglobin (Hp) 2-2 gene who took 400 International Units (IU) of vitamin E daily had more than 50 percent fewer heart attacks, strokes, and related deaths than Hp 2-2 patients who took a placebo pill. 40% of individuals with diabetes carry the Hp 2-2 gene.
- Vitamin E Could Help 40% of Diabetics Ward off Heart Attacks According to the Technion-Israel Institute of Technology
According to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel, citing a study published in the November 21 online edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology, people with the haptoglobin (Hp) 2-2 gene who took 400 International Units (IU) of vitamin E daily had more than 50 percent fewer heart attacks, strokes, and related deaths than Hp 2-2 patients who took a placebo pill. 40% of individuals with diabetes carry the Hp 2-2 gene.
- Vitamin E Could Help 40% of Diabetics Ward off Heart Attacks According to the Technion-Israel Institute of Technology
According to researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel, citing a study published in the November 21 online edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology, people with the haptoglobin (Hp) 2-2 gene who took 400 International Units (IU) of vitamin E daily had more than 50 percent fewer heart attacks, strokes, and related deaths than Hp 2-2 patients who took a placebo pill. 40% of individuals with diabetes carry the Hp 2-2 gene.
- Gencor Completes Successful Clinical Study On "Gencinia"
In a double blind, randomized, placebo controlled clinical trial, published in Diabetes Care, conducted on 60 patients with mild diabetes for a period of 90 days, Gencor's GENCINIA showed excellent results in controlling fasting and post prandial blood sugar and also in reducing glycosylated hemoglobin levels.
- Gencor Completes Successful Clinical Study On "Gencinia"
In a double blind, randomized, placebo controlled clinical trial, published in Diabetes Care, conducted on 60 patients with mild diabetes for a period of 90 days, Gencor's GENCINIA showed excellent results in controlling fasting and post prandial blood sugar and also in reducing glycosylated hemoglobin levels.
- Gencor Completes Successful Clinical Study On "Gencinia"
In a double blind, randomized, placebo controlled clinical trial, published in Diabetes Care, conducted on 60 patients with mild diabetes for a period of 90 days, Gencor's GENCINIA showed excellent results in controlling fasting and post prandial blood sugar and also in reducing glycosylated hemoglobin levels.
- Recent Study Shows the Prolibra® Weight Management Solution Significantly Reduces Glycemic Index Units
A recent human clinical trial shows that Prolibra® weight management solution from Glanbia Nutritionals considerably reduces postprandial glycemia in a dose dependant manner and resulted in a lower glycemic index (GI).
- Recent Study Shows the Prolibra® Weight Management Solution Significantly Reduces Glycemic Index Units
A recent human clinical trial shows that Prolibra® weight management solution from Glanbia Nutritionals considerably reduces postprandial glycemia in a dose dependant manner and resulted in a lower glycemic index (GI).
- Recent Study Shows the Prolibra® Weight Management Solution Significantly Reduces Glycemic Index Units
A recent human clinical trial shows that Prolibra® weight management solution from Glanbia Nutritionals considerably reduces postprandial glycemia in a dose dependant manner and resulted in a lower glycemic index (GI).
- Recent Study Shows the Prolibra® Weight Management Solution Significantly Reduces Glycemic Index Units
A recent human clinical trial shows that Prolibra® weight management solution from Glanbia Nutritionals considerably reduces postprandial glycemia in a dose dependant manner and resulted in a lower glycemic index (GI).
- Nestlé Researchers Discover a New Link between Gut Microbiota and Glucose Control
Studies at the Nestlé Research Center, Lausanne, Switzerland demonstrate that modulating gut microbiota improves the regulation of glycemic control and reverses the insulin resistance that occurs with obesity.
- Nestlé Researchers Discover a New Link between Gut Microbiota and Glucose Control
Studies at the Nestlé Research Center, Lausanne, Switzerland demonstrate that modulating gut microbiota improves the regulation of glycemic control and reverses the insulin resistance that occurs with obesity.
- Nestlé Researchers Discover a New Link between Gut Microbiota and Glucose Control
Studies at the Nestlé Research Center, Lausanne, Switzerland demonstrate that modulating gut microbiota improves the regulation of glycemic control and reverses the insulin resistance that occurs with obesity.
- Nestlé Researchers Discover a New Link between Gut Microbiota and Glucose Control
Studies at the Nestlé Research Center, Lausanne, Switzerland demonstrate that modulating gut microbiota improves the regulation of glycemic control and reverses the insulin resistance that occurs with obesity.
- Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
A study recently published in the Journal of the American College of Cardiology indicates that consuming a cocoa flavanol-rich beverage daily may have the potential to positively impact the blood vessel dysfunction associated with diabetes.
- Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
A study recently published in the Journal of the American College of Cardiology indicates that consuming a cocoa flavanol-rich beverage daily may have the potential to positively impact the blood vessel dysfunction associated with diabetes.
- Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
A study recently published in the Journal of the American College of Cardiology indicates that consuming a cocoa flavanol-rich beverage daily may have the potential to positively impact the blood vessel dysfunction associated with diabetes.
- New Preclinical Study in Rats Examines Superba Krill Oil Versus Fish Oil for Reduction of Fat in Heart and Liver
A study published in the Journal of Nutrition, Volume 139, Number 8, August 2009, follows a rat preclinical study performed for the biotechnological company Aker BioMarine, and examines the reduction of fat in the heart and the liver comparing Superba Krill Oil and omega-3 from fish oil.
- New Preclinical Study in Rats Examines Superba Krill Oil Versus Fish Oil for Reduction of Fat in Heart and Liver
A study published in the Journal of Nutrition, Volume 139, Number 8, August 2009, follows a rat preclinical study performed for the biotechnological company Aker BioMarine, and examines the reduction of fat in the heart and the liver comparing Superba Krill Oil and omega-3 from fish oil.
- New Preclinical Study in Rats Examines Superba Krill Oil Versus Fish Oil for Reduction of Fat in Heart and Liver
A study published in the Journal of Nutrition, Volume 139, Number 8, August 2009, follows a rat preclinical study performed for the biotechnological company Aker BioMarine, and examines the reduction of fat in the heart and the liver comparing Superba Krill Oil and omega-3 from fish oil.
- New Preclinical Study in Rats Examines Superba Krill Oil Versus Fish Oil for Reduction of Fat in Heart and Liver
A study published in the Journal of Nutrition, Volume 139, Number 8, August 2009, follows a rat preclinical study performed for the biotechnological company Aker BioMarine, and examines the reduction of fat in the heart and the liver comparing Superba Krill Oil and omega-3 from fish oil.
- New Preclinical Study in Rats Examines Superba Krill Oil Versus Fish Oil for Reduction of Fat in Heart and Liver
A study published in the Journal of Nutrition, Volume 139, Number 8, August 2009, follows a rat preclinical study performed for the biotechnological company Aker BioMarine, and examines the reduction of fat in the heart and the liver comparing Superba Krill Oil and omega-3 from fish oil.
- NXT Nutritionals Comments on Harvard Research Study on Blood Glucose Levels in the U.S.
NXT Nutritionals Holdings, Inc., has commented on a new research study from Harvard published in the Public Library of Science Medicine Journal Vol. 6, April, 2009. The study finds that high blood glucose levels is one of the most common killers of Americans, coming in as the fifth most deadly killer, after tobacco, high blood pressure, overweight/obesity and physical inactivity.
- NXT Nutritionals Comments on Harvard Research Study on Blood Glucose Levels in the U.S.
NXT Nutritionals Holdings, Inc., has commented on a new research study from Harvard published in the Public Library of Science Medicine Journal Vol. 6, April, 2009. The study finds that high blood glucose levels is one of the most common killers of Americans, coming in as the fifth most deadly killer, after tobacco, high blood pressure, overweight/obesity and physical inactivity.
- NXT Nutritionals Comments on Harvard Research Study on Blood Glucose Levels in the U.S.
NXT Nutritionals Holdings, Inc., has commented on a new research study from Harvard published in the Public Library of Science Medicine Journal Vol. 6, April, 2009. The study finds that high blood glucose levels is one of the most common killers of Americans, coming in as the fifth most deadly killer, after tobacco, high blood pressure, overweight/obesity and physical inactivity.
- NXT Nutritionals Comments on Harvard Research Study on Blood Glucose Levels in the U.S.
NXT Nutritionals Holdings, Inc., has commented on a new research study from Harvard published in the Public Library of Science Medicine Journal Vol. 6, April, 2009. The study finds that high blood glucose levels is one of the most common killers of Americans, coming in as the fifth most deadly killer, after tobacco, high blood pressure, overweight/obesity and physical inactivity.
- NXT Nutritionals Comments on Harvard Research Study on Blood Glucose Levels in the U.S.
NXT Nutritionals Holdings, Inc., has commented on a new research study from Harvard published in the Public Library of Science Medicine Journal Vol. 6, April, 2009. The study finds that high blood glucose levels is one of the most common killers of Americans, coming in as the fifth most deadly killer, after tobacco, high blood pressure, overweight/obesity and physical inactivity.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- New Company for “Change-The-World” Entrepreneurs™ Launches
- GMP Labs Expands Liquid Nutraceutical Capabilities
- What Parents Should Know About Kids and Supplements
- What Parents Should Know About Kids and Supplements
- Oats Beat Back Cholesterol
- Oats Beat Back Cholesterol
- Seniors: Pump Up for Strong Bones and Heart
- Seniors: Pump Up for Strong Bones and Heart
|
HOBOKEN, N.J., May 28, 2008 /PRNewswire via COMTEX/ -- A new study published in the May 2008 (volume 8, issue 25) edition of the journal of Nutrition Research shows Pycnogenol(R) (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, reduces blood sugar in type II diabetes patients, allows people to lower their antihypertensive medication and improves cardiovascular disease (CVD) risk factors. The study, conducted at the University of Arizona, Tucson, indicates Pycnogenol(R) may serve as a potent adjunct to prescription medications for the 20 million people in the Unites States living with diabetes.
"Most people with type II diabetes have cholesterol problems and half of those people experience hypertension. It has been documented that Pycnogenol(R) mediates a number of beneficial effects on the cardiovascular system for diabetics and healthy individuals," said Dr. Ronald Watson, a lead researcher of the study. "Previous studies have shown Pycnogenol(R) supplementation to be associated with reducing platelet aggregation, lowering LDL and increasing HDL cholesterol and modifying hypertension, among others. But what really makes the study results compelling is Pycnogenol(R) simultaneously lowered blood glucose, LDL cholesterol and blood pressure in patients. Furthermore, this is the first study suggesting that Pycnogenol(R) might also be beneficial in protecting kidney function in diabetics."
The 12-week, randomized, double-blind, placebo-controlled trial consisted of 48 men and women, 40 to 75 years of age, with noninsulin-dependent type II diabetes, taking anti-diabetic medication with metformin, sulfonylurea and glitazones. Furthermore, they took antihypertensive medications with ACE inhibitors such as Lisinopril. Despite their medication their fasting blood sugar was above healthy values (142 mg/dL) and their average systolic blood pressure was 139 mmHg subjects were randomly assigned to receive either Pycnogenol(R) (25 mg, 5 times daily) or matched placebo. Participants were instructed to continue taking their prescription medications.
Blood pressure and heart rate were recorded at baseline and at biweekly follow-up visits physicians tried to lower the patient's individual anti-hypertensive medication with aim to keep it below 130 mmHg. At monthly follow-up visits, all unused prescription medications were collected and counted. Change from baseline at weeks four, eight and 12 were calculated after eight hours of fasting for assessing plasma glucose, LDL cholesterol and endothelin-1. Urinary protein concentration was measured from spot urine samples on a monthly basis.
In the Pycnogenol(R) treated groups, results revealed Pycnogenol(R) achieved blood pressure control in 58.3 percent of patients at the end of the 12 weeks with 50 percent reduction in prescription medications. Plasma endothelin-1, a very potent hormone-like arterial constrictor which is typically elevated in diabetes patients, decreased by 17.8 percent. The constriction of arteries is believed to be the cause of hypertension and the decreased endothelin-1 with Pycnogenol(R) is suggested to be the cause for the healthier blood pressure. The mean average blood glucose decreased from high 142.3 mg/dL to a healthy value 118.6, a decrease by 16.7% after 12 weeks. Low-density lipoprotein cholesterol improved significantly, declining by 11.9%.
"It is amazing to see that adding Pycnogenol(R) to the regimen of prescription medication brought blood glucose to healthy levels, allowed half the patients to reach healthy blood pressure and enabled 58% to even lower their anti-hypertensive medication," said Watson. "An absolutely new finding is that Pycnogenol(R) appears to improve kidney function in diabetic people, this deserves more attention in future investigations. Pycnogenol(R) should be standard adjunct to pharmaceutical treatment of diabetic patients to help control an array of cardiovascular problems." In the past four years alone, numerous studies have been published on Pycnogenol's(R) health benefits for people living with diabetes. In a study published in the March 2004 Diabetes Care, Pycnogenol(R) was shown to lower blood sugar levels and not affect insulin levels. The October 2006 journal of Angiology revealed Pycnogenol(R) reduces diabetic microangiopathy and in 2006, published research in the July journal of Clinical and Applied Thrombosis/Hemostasis revealed Pycnogenol(R) heals leg ulcers in patients who suffer from diabetic leg ulcerations. Additionally, Pycnogenol(R) has been shown to reduce fasting and postprandial serum glucose levels and glycosylated hemoglobin in patients with type II diabetes. And, earlier studies with more than 1,000 diabetes patients, showed that Pycnogenol(R) has the ability to seal leaky capillaries in the eye. This capability stops the progression of vision loss in patients suffering from diabetic retinopathy, a diabetes-induced eye disease that ultimately leads to blindness.
About Pycnogenol(R) Pycnogenol(R) is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 35 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol(R) is available in more than 600 dietary supplements, multi-vitamins and health products worldwide. For more information, visit http://www.pycnogenol.com.
Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol(R) (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol(R) is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. NHS has the exclusive rights to market and sell Pycnogenol(R) in North America and benefits from more than 35 years of scientific research assuring the safety and efficacy of Pycnogenol(R) as a dietary supplement. For more information about Pycnogenol(R) visit our Web site at http://www.pycnogenol.com. |